Product Liability Lawyer Blog
The manufacturer of Eliquis is now claiming there has been a reduction in deaths for Afib patients who take the anticoagulant medication, but a review at the United States Food and Drug Administration is questioning this allegation, according to a recent news article from the Journal Sentinel.
Eliquis is one of what are now four new anticoagulants on the market to treat a medical condition known as atrial fibrillation (Afib). Afib is characterized as a disease associated with an irregular heartbeat that leads to the formation of blood clots, and, if these clots end up blocking blood to the brain, they can cause the patient to have a stroke. For this reason, the patient must take either a blood thinner, which was the preferred form of therapy for years, or one of the new oral anticoagulants (NOACs), including Xarelto, Eliquis, Pradaxa and Savaysa.
That last one, Savaysa, just received FDA approval and was brought to market earlier this year. Continue reading